BlackRock Institutional Trust’s Oncternal Therapeutics, Inc. Common Stock ONCT Stock Holding History

BlackRock Institutional Trust’s Portfolio ONCT Stock Details ONCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	$807K	Hold	1,092	–	–	﹤0.01%	3349
2016 Q3	$1.2M	Hold	1,092	–	–	﹤0.01%	3231
2016 Q2	$841K	Hold	1,092	–	–	﹤0.01%	3370
2016 Q1	$764K	Hold	1,092	–	–	﹤0.01%	3359
2015 Q4	$1.07M	Buy	1,092 +6	+0.6%	+$7.93K	﹤0.01%	3311
2015 Q3	$1.16M	Hold	1,086	–	–	﹤0.01%	3293
2015 Q2	$2.23M	Buy	1,086 +5	+0.5%	+$7.11K	﹤0.01%	3076
2015 Q1	$1.03M	Buy	1,081 +10	+0.9%	+$9.94K	﹤0.01%	3330
2014 Q4	$1.09M	Hold	1,071	–	–	﹤0.01%	3328
2014 Q3	$1.11M	Buy	1,071 +51	+5%	+$75.2K	﹤0.01%	3288
2014 Q2	$1.97M	Sell	1,020 -44	-4%	-$87.1K	﹤0.01%	3199
2014 Q1	$2.28M	Buy	1,064 +137	+15%	+$341K	﹤0.01%	3115
2013 Q4	$2.14M	Buy	927 +240	+35%	+$549K	﹤0.01%	3131
2013 Q3	$1.95M	Sell	687 -297	-30%	-$1.48M	﹤0.01%	3143
2013 Q2	$9.09M	Buy	+984	New	+$7.58M	﹤0.01%	2373

Other funds holding ONCT

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

FHA

First Horizon Advisors Memphis, Tennessee $3.85B AUM 16.99% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

DAM

Delta Asset Management Memphis, Tennessee $1.1B AUM 14.89% 1-Year Est. Return

BlackRock Advisors Wilmington, Delaware $98.8B AUM 39.77% 1-Year Est. Return

KLI

Kelman-Lazarov Inc Memphis, Tennessee $698M AUM 14.07% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return

BlackRock Institutional Trust's ONCT Position: Q4 2016 in Review

BlackRock Institutional Trust held its Oncternal Therapeutics, Inc. Common Stock (ONCT) position steady in Q4 2016 at 1,092 shares worth $807K. The position accounts for ﹤0.01% of the portfolio, ranked #3349.

BlackRock Institutional Trust first reported a position in ONCT in Q2 2013 and has held it in 15 quarters since. The position peaked at $9.09M in Q2 2013. 21 funds tracked by Wall St. Rank hold ONCT as of Q4 2016.

BlackRock Institutional Trust held 1,092 shares of Oncternal Therapeutics, Inc. Common Stock worth $807K as of Q4 2016.
BlackRock Institutional Trust left its Oncternal Therapeutics, Inc. Common Stock share count unchanged in Q4 2016.
Oncternal Therapeutics, Inc. Common Stock made up ﹤0.01% of BlackRock Institutional Trust's portfolio in Q4 2016, its #3349 holding.
BlackRock Institutional Trust first reported a position in Oncternal Therapeutics, Inc. Common Stock in Q2 2013 and has held it in 15 quarters since.
BlackRock Institutional Trust's Oncternal Therapeutics, Inc. Common Stock position peaked at $9.09M in Q2 2013.
21 funds tracked by Wall St. Rank held Oncternal Therapeutics, Inc. Common Stock as of Q4 2016.

Based on BlackRock Institutional Trust's 13F filing for Q4 2016, filed 10 Feb 2017.